---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-22-000070"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:16:53.714994+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q3 net loss $107.7M ($1.89/share); ZORYVE launch generates $0.7M revenue

## Summary
- Net product revenue of $0.7M from ZORYVE launch; about half from wholesaler inventory build.
- Net loss $107.7M ($1.89 per share) vs $57.0M ($1.14) YoY; Ducentis acquisition added $0.51 per share.
- R&D expenses $69.7M (incl. $30M Ducentis upfront); SG&A $35.5M on launch costs.
- Cash, equivalents, and marketable securities $478.2M; $162M from Aug 2022 public offering and $125M debt draw.
- Positive topline Phase 3 data for roflumilast foam in scalp/body psoriasis; enrollment completed in atopic dermatitis trials.

## SEC filing metadata
- accession: 0001787306-22-000070
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000070/0001787306-22-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000070/arqt-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-22-000070
- JSON: https://secwatch.observer/filing/0001787306-22-000070.json
- Plain text: https://secwatch.observer/filing/0001787306-22-000070.txt

## Key facts
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) issued a press release relating to its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000070/0001787306-22-000070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.